Article Summary
张婉馨,彭丽艳,贺 巍,李小露,熊 果,陈立桁.沙库巴曲缬沙坦联合胺碘酮对老年HF伴PAF患者心功能、炎症因子及神经内分泌激素的影响[J].现代生物医学进展英文版,2021,(2):254-258.
沙库巴曲缬沙坦联合胺碘酮对老年HF伴PAF患者心功能、炎症因子及神经内分泌激素的影响
Effects of Sakubatrevalsartan Combined with Amiodarone on Cardiac Function, Inflammatory Factors and Neuroendocrine Hormones in Elderly Patients with HF and PAF
Received:June 26, 2020  Revised:July 22, 2020
DOI:10.13241/j.cnki.pmb.2021.02.012
中文关键词: 沙库巴曲缬沙坦  胺碘酮  老年  心力衰竭  阵发性房颤  心功能  炎症因子  神经内分泌激素
英文关键词: Sakubatrevalsartan  Amiodarone  Old age  Heart failure  Paroxysmal atrial fibrillation  Cardiac function  Inflammatory factor  Neuroendocrine hormone
基金项目:广东省公益研究和能力建设专项资金项目(2014A020212413)
Author NameAffiliationE-mail
张婉馨 南方医科大学珠江医院药剂科 广东 广州 510000 japiet@163.com 
彭丽艳 南方医科大学珠江医院药剂科 广东 广州 510000  
贺 巍 南方医科大学珠江医院药剂科 广东 广州 510000  
李小露 南方医科大学珠江医院药剂科 广东 广州 510000  
熊 果 南方医科大学珠江医院药剂科 广东 广州 510000  
陈立桁 南方医科大学珠江医院心内科 广东 广州 510000  
Hits: 1000
Download times: 575
中文摘要:
      摘要 目的:探讨沙库巴曲缬沙坦联合胺碘酮对老年心力衰竭(HF)伴阵发性房颤(PAF)患者心功能、神经内分泌激素以及炎症因子的影响。方法:选取2017年2月~2019年1月期间我院收治的80例老年HF伴PAF患者,根据随机数字表法分为研究组(n=40,沙库巴曲缬沙坦联合胺碘酮治疗)和对照组(n=40,胺碘酮治疗),比较两组患者疗效、心功能指标[左心室舒张末期内径(LVEDD)、左心室射血分数(LVEF)、左心室收缩末期内径(LVESD)]、炎症因子[白介素-33(IL-33)、肿瘤坏死因子-α(TNF-α)、细胞间黏附分子-1(ICAM-1)]及神经内分泌激素(去甲肾上腺素、醛固酮和血管紧张素Ⅱ)水平及不良反应发生情况。结果:研究组治疗3个月后的临床总有效率90.00%(36/40)高于对照组67.50%(27/40)(P<0.05)。两组治疗3个月后LVEDD、ICAM-1、TNF-α、LVESD、IL-33均较治疗前降低,且研究组较对照组低(P<0.05);LVEF较治疗前提高,且研究组高于对照组(P<0.05)。两组不良反应总发生率比较无差异(P>0.05)。两组治疗3个月后去甲肾上腺素、醛固酮、血管紧张素Ⅱ水平均较治疗前降低,且研究组低于对照组(P<0.05)。结论:老年HF伴PAF患者在胺碘酮的基础上联合沙库巴曲缬沙坦治疗,心功能指标改善显著,血清炎症因子及神经内分泌激素水平有所降低,且安全可靠,疗效显著。
英文摘要:
      ABSTRACT Objective: To investigate the effects of sakubatrevalsartan combined with amiodarone on cardiac function, inflammatory factors and neuroendocrine hormones in elderly patients with congestive heart failure (CHF) and paroxysmal atrial fibrillation (PAF). Methods: From February 2017 to January 2019, A total of 80 elderly patients with CHF and PAF who were admitted to our hospital were selected, they were divided into study group (n=40, sakubatrevalsartan combined with amiodarone) and control group (n=40, amiodarone) according to the random number table method. The efficacy and cardiac function indexes [left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF), left ventricular end systolic diameter (LVESD)], inflammation factors [interleukin-33 (IL-33), tumor necrosis factor-α (TNF-α), intercellular adhesion molecule 1 (ICAM 1)] and neuroendocrine hormones (norepinephrine, aldosterone and angiotensin Ⅱ) levels and adverse reactions occured of the two groups were compared. Results: The total clinical effective rate of the study group after 3 months was 90.00%(36/40) higher than 67.50%(27/40) of the control group (P<0.05). 3 months after treatment, LVEDD, ICAM-1, TNF-α LVESD and IL-33 of the two groups were reduced compared with those before treatment, and the study group was lower than the control group (P<0.05). LVEF was higher than that before treatment, and the study group was higher than the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Norepinephrine, aldosterone and angiotension Ⅱ of the two groups at 3 months after treatment decreased compared with those before treatment, and study group was lower than control group (P<0.05). Conclusion: On the basis of amiodarone treatment, elderly patients with HF and PAF use the sakubatrevalsartan treat showed significant improvement in cardiac function indexes, decreased levels of serum inflammatory factors and neuroendocrine hormones, which are safe, reliable and effective.
View Full Text   View/Add Comment  Download reader
Close